1. Home
  2. GH vs SEM Comparison

GH vs SEM Comparison

Compare GH & SEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$100.63

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo Select Medical Holdings Corporation

SEM

Select Medical Holdings Corporation

HOLD

Current Price

$15.25

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
SEM
Founded
2011
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Hospital/Nursing Management
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
1.9B
IPO Year
2018
2009

Fundamental Metrics

Financial Performance
Metric
GH
SEM
Price
$100.63
$15.25
Analyst Decision
Strong Buy
Buy
Analyst Count
21
3
Target Price
$92.90
$16.33
AVG Volume (30 Days)
2.3M
1.2M
Earning Date
10-29-2025
10-30-2025
Dividend Yield
N/A
1.64%
EPS Growth
N/A
N/A
EPS
N/A
0.87
Revenue
$902,569,000.00
$5,368,760,000.00
Revenue This Year
$34.72
$5.53
Revenue Next Year
$26.46
$4.33
P/E Ratio
N/A
$17.46
Revenue Growth
30.38
45.29
52 Week Low
$29.91
$11.65
52 Week High
$112.43
$20.83

Technical Indicators

Market Signals
Indicator
GH
SEM
Relative Strength Index (RSI) 51.45 60.92
Support Level $100.21 $15.18
Resistance Level $105.01 $15.80
Average True Range (ATR) 4.02 0.36
MACD -1.64 0.02
Stochastic Oscillator 23.04 46.15

Price Performance

Historical Comparison
GH
SEM

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About SEM Select Medical Holdings Corporation

Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.

Share on Social Networks: